Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies.
Saved in:
| Title: | Remdesivir for Treatment of COVID-19 Requiring Oxygen Support: A Cross-Study Comparison From 2 Large, Open-Label Studies. |
|---|---|
| Authors: | Fusco D; Department of Medicine, Tulane Medical Center, New Orleans, Louisiana, USA., Malenica I; Real World Evidence, Gilead Sciences, Inc., Foster City, California, USA.; Department of Biostatistics, University of California, Berkeley, Berkeley, California, USA., Günthard HF; Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, Zurich, Switzerland.; Institute of Medical Virology, University of Zurich, Zurich, Switzerland., Gupta SK; Division of Infectious Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA., Kurbegov D; Sarah Cannon, Nashville, Tennessee, USA., Balani B; Hackensack School of Medicine, Hackensack University Medical Center, Hackensack, New Jersey, USA., Olender S; Department of Internal Medicine, Columbia University in the City of New York, New York, New York, USA., Aberg JA; Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Telep LE; Real World Evidence, Gilead Sciences, Inc., Foster City, California, USA., Tian Y; Clinical Bioinformatics and Exploratory Analytics, Gilead Sciences, Inc., Foster City, California, USA., Blair C; Biostatistics, Gilead Sciences, Inc., Foster City, California, USA., Wu G; Biostatistics, Gilead Sciences, Inc., Foster City, California, USA., Haubrich RH; Global Medical Affairs, Gilead Sciences, Inc., Foster City, California, USA., Wang CY; Global Medical Affairs, Gilead Sciences, Inc., Foster City, California, USA., Chokkalingam AP; Real World Evidence, Gilead Sciences, Inc., Foster City, California, USA.; Division of Epidemiology, School of Public Health, University of California, Berkeley, California, USA., Osinusi AO; Clinical Development, Gilead Sciences, Inc., Foster City, California, USA., Wendtner CM; Munich Clinic Schwabing, Academic Teaching Hospital, Ludwig-Maximilians-University, Munich, Germany., Gottlieb RL; Center for Advanced Heart and Lung Disease, Baylor University Medical Center, Dallas, Texas, USA.; Department of Internal Medicine, Texas A&M Health Science Center, Dallas, Texas, USA.; Department of Internal Medicine, Burnett School of Medicine at TCU, Fort Worth, Texas, USA.; Baylor Scott & White Research Institute, Dallas, Texas, USA. |
| Source: | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Nov 22; Vol. 79 (5), pp. 1182-1189. |
| Publication Type: | Journal Article; Comparative Study; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Oxford University Press Country of Publication: United States NLM ID: 9203213 Publication Model: Print Cited Medium: Internet ISSN: 1537-6591 (Electronic) Linking ISSN: 10584838 NLM ISO Abbreviation: Clin Infect Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 1537-6591 |
|---|---|
| DOI: | 10.1093/cid/ciae336 |
